Stockreport

Beam Therapeutics: Pivoting From Platform To Execution Stage [Seeking Alpha]

Beam Therapeutics Inc.  (BEAM) 
PDF BEAM-302's "in vivo" gene editing for AATD achieved a potential FDA accelerated approval pathway, derisking the lead pipeline and providing a major 2026 catalyst. Ris [Read more]